20-F: Ehave Inc. Reports Full Year 2023 Results Amidst Going Concern Uncertainty

Ehave Inc. reported a net loss of $2.4 million for 2023 and faces substantial doubt about its ability to continue as a going concern without additional capital.

Summary

• Ehave Inc. reported a net loss of $2,409,396 for the fiscal year ended December 31, 2023, compared to a net loss of $5,091,470 in 2022.
• The company's accumulated deficit reached $36,173,767 as of December 31, 2023.
• Ehave had no significant revenues from continuing operations in both 2023 and 2022.
• General and administrative expenses decreased by 52% to $1,594,124 in 2023, primarily due to reduced stock-based compensation and consulting fees.
• The company's total assets were $2,972,925, and it had a shareholders deficit of $5,668,263 as of December 31, 2023.
• Ehave's independent auditors have expressed concern about the company's ability to continue as a going concern without significant additional capital.
• The company's ability to continue operations is dependent on its ability to raise additional capital.
• Ehave is developing a mental health data platform and digital therapeutic applications, including MegaTeam, Ninja Reflex, and KetaDash.
• The company is focusing on expanding its product offerings and forming strategic alliances to support its growth.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses, no revenue, and a going concern warning. While there are some positive aspects like reduced expenses and product development, the overall outlook is negative due to the company's financial instability and dependence on future capital raises.

Positives

• The company's net loss decreased significantly from $5.1 million in 2022 to $2.4 million in 2023.
• General and administrative expenses were reduced by 52% in 2023, indicating improved cost management.
• Ehave is actively developing digital therapeutic applications and a mental health data platform, which could provide future revenue streams.
• The company is exploring various financing options, including equity funding and strategic collaborations.

Negatives

• Ehave has incurred significant operating losses and has an accumulated deficit of $36.2 million.
• The company has not generated any significant revenues to date.
• Ehave's independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company is currently in default on its convertible notes.
• Ehave has a working capital deficit of $7.6 million as of December 31, 2023.

Risks

• Ehave's limited operating history makes evaluating its business and future prospects difficult.
• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• If Ehave is unable to obtain additional funding, its business operations will be harmed.
• The company's products may not be successful in gaining market acceptance.
• Ehave may not be able to keep up with rapid technological changes in its field.
• The company faces competition from better-established companies with greater resources.
• Ehave has identified material weaknesses in its internal control over financial reporting.
• The market for the company's products is immature and volatile.
• The company's security measures could be breached, leading to unauthorized access to customer data.
• Ehave may not be in compliance with rules and regulations of the U.S. Food and Drug Administration (FDA) should they become applicable to any products they develop in the future.

Future Outlook

The company anticipates continuing to incur losses and negative cash flows as it develops and commercializes its products. Ehave plans to raise capital through equity offerings, debt financings, and strategic partnerships to fund its operations.

Management Comments

• Management intends to take guidance into consideration as we work to resolve this weakness.
• Management plans include the continued commercialization of our products and raising capital through a combination of equity offerings, debt financings, other third-party funding and other collaborations and strategic partnerships.

Industry Context

The company operates in the emerging digital therapeutics and mental health technology market, which is characterized by rapid technological advancements and increasing competition. The market for software-based systems for mental health or treatments using psychedelics is a new and unproven market, and it is uncertain whether it will achieve and sustain demand and market adoption.

Comparison to Industry Standards

• Ehave's financial performance is significantly below industry standards for established software and healthcare companies, as it has not generated significant revenue and is operating at a loss.
• Compared to competitors like Akili Interactive, Attentiv, Myndlift, and C8Sciences, which are also developing digital therapeutics, Ehave is at an earlier stage of commercialization and faces greater financial uncertainty.
• Unlike established EHR systems from Epic, Allscripts, and GE Healthcare, Ehave's KetaDash program is focused on a niche market (Ketamine clinics) and has not yet achieved significant market penetration.
• Companies like Novamind and Field Trip Health, which offer Ketamine infusion therapy, have established physical clinics, while KetaDash differentiates itself by providing in-home treatments, which may offer a competitive advantage but also presents unique operational challenges.

Related Party Transactions

• The company has entered into consulting contracts with its officers.
• The company has an executive consulting agreement with its CEO, Benjamin Kaplan.
• The company has a consulting agreement with its CFO, James Cardwell.
• The company has an executive employment agreement with its Chief Technology Officer.

Stakeholder Impact

• Shareholders face a high risk of losing their investment due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential layoffs or reduced compensation if the company is unable to secure additional funding.
• Customers may be affected by potential disruptions in service or product development if the company faces financial difficulties.
• Suppliers and creditors face the risk of non-payment if the company is unable to continue operations.

Next Steps

• The company plans to continue the commercialization of its products.
• Ehave intends to raise capital through a combination of equity offerings, debt financings, other third-party funding and other collaborations and strategic partnerships.
• The company will continue to develop the Ehave Dashboard, MegaTeam, and Ninja Reflex products.

Key Dates

Keywords

mental health, digital therapeutics, software, cognitive assessment, rehabilitation, psychedelics, ketamine, Ehave Dashboard, MegaTeam, Ninja Reflex, KetaDash, financial results, going concern, capital raise